poisar

Stocks · News reference

Jefferies Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk

Jefferies analyst Michael Toomey initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Buy rating and announces Price Target of $30.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BBNX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Robbins Llp

    BBNX Stockholders Have Rights – If You Lost Money Investing in Beta Bionics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

    Robbins LLP announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company downplayed FDA Form 483 concerns in October 2025, claiming issues were minor, but the FDA's February 2026 warning letter revealed serious malfunctions causing dangerous insulin overdoses. BBNX stock plummeted from $31.99 to $12.89 per share between January and February 2026. Investors who suffered losses during the class period (July 30, 2025 - February 24, 2026) may be eligible to recover damages.

    BBNX